| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
STORY UPDATE
SOUTH SAN FRANCISCO—September 21, 2007—Citing their substantial progress to date, Exelixis announced it has extended its research collaboration with BMS to develop and commercialize therapeutic compounds against the liver X receptor. The agreement will extend through January 2009, with an option for a further one-year extension, and will see Exelixis receive further research funding to the tune of $7.5 million.
 
 
SOUTH SAN FRANCISCO—With an initial payment of $60 million, Exelixis announced it had entered into a discovery and development collaboration with BMS for three mutually selected oncology targets. The smaller biotech company will apply its drug discovery platform to identify lead small molecule candidates and take them through preclinical testing. BMS then retains the rights to select up to three INDs, for which Exelixis will receive another $20 million each.
 
"We have a long-standing and productive history of collaboration with Exelixis and are pleased to expand our partnership to include the discovery and development of novel, targeted oncology therapies," said Dr. Francis Cuss, SVP of Drug Discovery for BMS.
 
The companies will share equally in the development costs, commercial profits and co-promotion responsibilities in the United States, with Exelixis receiving royalties on any products sold elsewhere. The biotech may opt out of the co-development and co-promotion efforts and instead receive milestone and royalty payments in lieu of U.S. profit sharing.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue